| [1] 张国威, 邵长庚, 王光超. 我国银屑病的年发病率及年龄易患率[J]. 中华皮肤科杂志. 1987, 20(129): 134.
[2] El-Darouti MA. Different Granulomatous and Pustular Skin Lesions Caused by One Underlying Disorder. In: Challenging Cases in Dermatology: Springer; 2013:631-643.
[3] McInnes IB, Kavanaugh A, Gottlieb AB et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial[J]. The Lancet. 2013.
[4] Igarashi A, Kato T, Kato M et al. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial[J]. J Dermatol. 2012, 39(3): 242-252.
[5] Krueger GG, Langley RG, Leonardi C et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis[J]. New England Journal of Medicine. 2007, 356(6): 580-592.
[6] Leonardi CL, Kimball AB, Papp KA et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)[J]. The Lancet. 2008, 371(9625): 1665-1674.
[7] O'Neill JL, Kalb RE. Ustekinumab in the therapy of chronic plaque psoriasis[J]. Biologics. 2009, 3: 159-168.
[8] Papp KA, Langley RG, Lebwohl M et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)[J]. Lancet. 2008, 371(9625): 1675-1684.
[9] Tsai TF用, Ho JC, Song M et al. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)[J]. J Dermatol Sci. 2011, 63(3): 154-163.
[10] Kim N, Gottlieb AB. Psoriasis: Ustekinumab and Other Biologics in the Pipeline[J]. Current Dermatology Reports. 2012, 1(3): 108-114.
[11] Daniel AS. The Therapeutic Approach to Psoriasis[J]. 15 The Therapeutic Approach to Psoriasis. 2012: 15.
[12] Temple R. Past, Present, and Future of Drug Safety Assessment. In: Proceedings of the Fourth Seattle Symposium in Biostatistics: Clinical Trials; 2013: Springer; 2013. p. 157-173.
[13] Geng Y, Fu J, Sarkis J et al. Towards a national circular economy indicator system in China: an evaluation and critical analysis[J]. Journal of Cleaner Production. 2012, 23(1): 216-224.
|
